At the IGTP TODAY

News

The GCAT|Panel is the first complete genetic map of the Iberian population that helps identifying possible genetic causes of common diseases

The panel is the result of a collaboration between the GCAT|Genomes for Life Cohort of the IGTP and the Barcelona Supercomputing Center. Massive genome sequencing of a sample of healthy members of the population has made it possible to provide a genetic tool to study complex variants in the genome that can potentially cause common diseases. The panel will allow researchers using low-cost sequencing techniques to improve the discovery and interpretation of the genetic changes behind common diseases more easily

- Research

The generation of human neurofibromas in mice opens the door to testing new treatments

The Hereditary Cancer Group have published a study in Cell Reports in which they describe the generation of a model system based on induced pluripotent stem cells (iPSCs) that is able to generate human neurofibromas in mice. These tumours arise in people with the genetic disease Neurofibromatosis Type 1, a prevalent condition occurring in one in every 3,000 people. To date, a robust method for generating human neurofibromas in mice has been lacking, and the model developed opens up the possibility of testing new treatments for these tumours.

- Research

The RIGHT PLUS Network presents the results of the LAMIS study on sexual health in gay men and MSN in Latin America

The RIGHT PLUS Network has presented the executive summary of the Latin American MSM (men who have sex with men) Internet Survey (LAMIS-20218), in which 64,655 men who have sex with men in Latin America responded to a questionnaire on physical and mental health. The CEEISCAT (Centre for Epidemiological Studies of Sexually Transmitted Disease and AIDS in Catalonia), a research group at the IGTP is part of the international consortium Coalition Plus, which carried out LAMIS-18.

- Institutional

952,000 euros for the IGTP Spin-Off Biointaxis to develop gene therapy for Friedriech’s ataxia

Biointaxis, spin-off company from the Germans Trias i Pujol Research Institute (IGTP) has closed a financing round of 952,000 euros on the Capital Cell Platform. The company will use the investment to advance the pre-clinical research for their treatment for Friedriech's ataxia, a rare progressive degenerative disease. The studies aim to validate the safety of their treatment.

- Institutional

The new clinical trial CONSTAN testing of effectiveness of the RUTI® vaccine to shorten tuberculosis treatment times

The biotechnology company Archivel Farma has designed and set up a phase IIb clinical study called CONSTAN to explore whether administering the immunotherapy RUTI®, known as the RUTI® vaccine, along with the standard treatment for patients with pulmonary tuberculosis (TB) improves results. The principal investigator of the project is Dr Cristina Vilaplana, leader of the Experimental Tuberculosis Unit (UTE) at the Germans Trias I Pujol Research Institute (IGTP). The study has been approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the First Patient In will be welcomed in January 2022

- Institutional

Presentation of the ACROFACE project at Germans Trias for early detection of people with acromegaly

The Endocrine, Thyroid and Obesity Research Group led by Dr Manel Puig Domingo and the Universitat Rovira i Virgili (URV) spin-off company UP2SMART have created an artificial intelligence that can detect early facial changes in photographs.  The software opens the door for an early detection system for acromegaly, a rare disease which produces deformities in facial and skeletal bone structure and has a range of other effects such as cardiac problems, diabetes and cancer. It is frequently diagnosed 10 years after onset, which leads to further complications.

- Research

Air pollution does not increase the risk of getting infected but does increase the risk of getting sick from COVID-19

Long-term exposure to air pollution is associated with a higher risk of developing COVID-19 among those people who get infected, shows the COVICAT Study led by the Barcelona Institute of Global Health (ISGlobal), a centre supported by the "la Caixa" Foundation, and co-led by the GCAT' Genomes for Life-Germans Trias i Pujol Research Institute (IGTP), Badalona. The study, published in Environment Health Perspectives, provides further evidence on the health benefits of reducing air pollution.